Affordable Access

Publisher Website

Mammalian Target of Rapamycin Inhibitors in Combination with Letrozole in Breast Cancer

Authors
Journal
Clinical Breast Cancer
1526-8209
Publisher
Elsevier
Publication Date
Volume
7
Issue
4
Identifiers
DOI: 10.3816/cbc.2006.n.047
Keywords
  • Everolimus
  • Hormonal Therapy
  • Survival
  • Temsirolimus
Disciplines
  • Biology
  • Medicine

Abstract

Abstract Breast cancer is the most common malignancy and the second most common cause of cancer-related death in women. Endocrine therapy has been used for more than a century to treat advanced-stage breast cancer. The results obtained with the third-generation aromatase inhibitor letrozole demonstrated an actual improvement in patient outcome compared with tamoxifen. This benefit translates into disease-free survival improvement for adjuvant treatment and overall survival in patients with metastatic disease. The present clinical situation of hormonal therapy is stable; however, recently, new anticancer agents (temsirolimus and everolimus) that inhibit mammalian target of rapamycin protein kinase have been developed and seem to be very promising because of their synergistic activity with letrozole. The phase II study of a combination of temsirolimus or everolimus with letrozole demonstrated a better progression-free survival in the combination arm than in the letrozole alone arm. Consequently, the results of ongoing phase III studies are eagerly awaited.

There are no comments yet on this publication. Be the first to share your thoughts.